GlassScriptPhysician profile
Stacy Norman
NPI 1417146655
$7,995.78
in general payments reported to CMS, 2019-2025
25 companies · $2,829 in 2025
The $2,829 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $760 · 2022: $262 · 2023: $1,813 · 2024: $2,332 · 2025: $2,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,793 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,793.18 |
| Education | $180.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $956.68 | 2021-2025 | |
| Pfizer INC. | $830.71 | 2021-2025 | |
| Galderma Laboratories, L.P. | $797.57 | 2021-2025 | Nemluvio, Dysport |
| Arcutis Biotherapeutics, INC. | $638.09 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $609.14 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $570.84 | 2023-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $499.06 | 2024-2025 | Bimzelx |
| Amgen INC. | $470.52 | 2022-2024 | Otezla |
| Genzyme Corporation | $464.97 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $301.69 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $295.66 | 2021-2025 | Adbry |
| Incyte Corporation | $283.28 | 2022-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $267.80 | 2022-2025 | |
| Lilly USA, LLC | $255.21 | 2023 | Taltz, Olumiant |
| Journey Medical Corporation | $251.86 | 2021-2025 | Emrosi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $137.36 | 2025 | Sotyktu |
| Biofrontera INC. | $136.35 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $51.90 | 2022 | |
| Sun Pharmaceutical Industries INC. | $43.97 | 2023-2025 | Winlevi |
| Almirall LLC | $42.52 | 2025 | Klisyri |
| Glaxosmithkline, LLC. | $32.96 | 2023 | Bexsero, Shingrix |
| Merck Sharp & Dohme LLC | $20.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.60 | 2021 | |
| Lnhc, INC | $14.67 | 2025 | Zelsuvmi |
| Mayne Pharma Commercial LLC | $5.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Norman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.